-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Preliminary first-in-human trial data for BioNTech's CAR-T cell product, either as a monotherapy or in combination with an mRNA vaccine called CARVac, show that the therapy appears to be safe and shows early-stage progress in patients with advanced solid tumors Efficacy signs
CAR-T
CAR-T cell therapy has revolutionized the treatment options for hematological malignancies.
FDA Leukemia Lymphoma
Among 14 patients with relapsed or refractory advanced, CLDN6 + solid tumors, evaluable for efficacy 6 weeks after infusion of CAR-T cell therapy, 4 patients with testicular cancer and 2 patients with ovarian cancer experienced partial responses (PR), The overall response rate was nearly 43 %
Among 14 patients with relapsed or refractory advanced, CLDN6 + solid tumors, evaluable for efficacy 6 weeks after infusion of CAR-T cell therapy, 4 patients with testicular cancer and 2 patients with ovarian cancer experienced partial responses (PR), The overall response rate was nearly 43 %
immunity
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5545497 https://firstwordpharma.
com/story/5545497
Leave a comment here